Copyright
©The Author(s) 2020.
World J Diabetes. Aug 15, 2020; 11(8): 358-369
Published online Aug 15, 2020. doi: 10.4239/wjd.v11.i8.358
Published online Aug 15, 2020. doi: 10.4239/wjd.v11.i8.358
Table 1 Syringe provision and costs
Setting | % of settings where syringes are free of charge | Mean (range), range, costs of a syringe to the patient (for systems not providing for free) |
Public health system | 47.4 | $0.27, $0.04 (Uzbekistan)-$0.97 (Tajikistan) |
Private retail pharmacy | 0.0 | $0.29, $0.07 (Eritrea)-$1.25 (Bolivia) |
Public health insurance program | 50.0 | $0.19, $0.10 (Burundi)-$0.28 (Nigeria) |
Table 2 Syringe volume and needle length and gauge
Syringe volume (n = 37) | |||||
1 mL/cc | 0.5 mL/cc | 0.3 mL/cc | |||
Percentage | 42.9 (n = 15) | 34.3 (n = 12) | 22.9 (n = 8) | ||
Needle length (n = 33) | |||||
5/16” (8 mm) | 3/16” (5 mm) | 1/8” (4 mm) | |||
Percentage | 36.4 (n = 12) | 48.5 (n = 16) | 15.2 (n = 5) | ||
Needle gauge (n = 32) | |||||
28 | 29 | 30 | 31 | ||
Percentage | 43.8 (n = 14) | 15.6 (n = 5) | 15.6 (n = 5) | 25.0 (n = 8) |
Table 3 Injection sites encouraged by diabetes centres
Injection sites | Number (%) of centres |
Thighs | 36 (97.2) |
Stomach | 35 (94.5) |
Back of arm | 21 (56.7) |
Buttocks | 19 (51.3) |
Front of arm | 12 (32.4) |
Other | 1 (2.7) |
Table 4 Ages recommended to begin self-administration of insulin injection
Age (yr) | Number (%) of centres |
≤ 5 | 3 (10.0) |
6 | 4 (13.3) |
7 | 2 (6.7) |
8 | 6 (20.0) |
9 | 2 (6.7) |
10 | 9 (30.0) |
11 | 1 (3.3) |
≥ 12 | 3 (10.0) |
Table 5 Needle reuse
Times needle used before disposal | Number (n %) of centres |
Single use | 2 (5.7) |
Two to four | 18 (51.4) |
Five to nine | 10 (28.6) |
Ten or more | 5 (14.3) |
Table 6 Glycated haemoglobin provision within the 29 countries that had some public health provision
Provision | Measurement methods | Costs per test | Availability | |||||
Level (s) of health system settings | Frequency of provision in defined setting | POCT | Laboratory analysis | Both | Number (percentage) providing at no cost to patient | Mean cost to patient (when not provided for free) | Range of cost to patient | Mean availability (when provided) |
Primary health care facility | 6 (20.7) | 3 | 3 | 0 | 2 (33.3) | $10.95 | $6.44 (Dominican Republic)-$17.41 (Philippines) | 62.5% |
District and regional hospitals | 27 (93.1) | 7 | 15 | 5 | 4 (14.8) | $9.74 | $4.00 (Ethiopia and Uzbekistan)-$27.75 (St Lucia) | 67.5% |
Tertiary hospital | 26 (89.7) | 4 | 18 | 4 | 9 (34.6) | $11.92 | $4.00 (Ethiopia)-$29.00 (Central African Republic) | 75.5% |
Table 7 Main challenges in providing glycated haemoglobin testing
Challenge | Number (%) of centres reporting this challenge |
Cartridge cost | 23 (70.9) |
Stockouts | 22 (68.8) |
Maintenance of testing machine | 21 (65.6) |
Machine cost | 18 (56.3) |
Adequate supplies | 15 (46.9) |
Trained staff | 15 (46.9) |
Refrigeration | 11 (34.4) |
Adequate oversight of supplies | 9 (28.1) |
Other challenges | 8 (25.0) |
- Citation: Klatman EL, Ogle GD. Access to insulin delivery devices and glycated haemoglobin in lower-income countries. World J Diabetes 2020; 11(8): 358-369
- URL: https://www.wjgnet.com/1948-9358/full/v11/i8/358.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i8.358